# 5-Component Handoff Report — Reviewer 1 (Milestone 4 Peer Review)

**Agent:** Reviewer 1 (Senior Clinical & Pharmacological Peer Reviewer)  
**Working Directory:** `C:\vazus\.agents\reviewer_m4_1`  
**Target Document Reviewed:** `C:\vazus\.agents\orchestrator\M3_actionable_protocol.md`  
**Date:** July 23, 2026  

---

## 1. Observation
- **Target File Examined**: `C:\vazus\.agents\orchestrator\M3_actionable_protocol.md` (507 lines, 53,728 bytes).
- **Core Elements Audited**:
  - Vitamin D3 ($4,000\text{--}5,000\ \text{IU/day}$) + Vitamin K2 MK-7 ($100\text{--}200\ \mu\text{g/day}$).
  - Bioavailable Magnesium Matrix ($400\text{--}600\ \text{mg}$ elemental $\text{Mg}^{2+}$).
  - Zinc Bisglycinate ($15\text{--}30\ \text{mg}$ elemental) + Copper Bisglycinate ($1.5\text{--}2.0\ \text{mg}$ elemental), yielding a $\text{Zn:Cu}$ ratio of $10:1$ to $15:1$.
  - Boron ($6\text{--}10\ \text{mg}$ elemental, pulsed 2w ON / 1w OFF schedule).
  - Selenium ($50\text{--}100\ \mu\text{g/day}$ routine maintenance, modified from $100\text{--}200\ \mu\text{g}$ due to SELECT trial findings).
  - Micronized Creatine Monohydrate ($5\ \text{g/day}$) & Methylated B-Complex (L-5-MTHF, P5P, Methyl-B12).
  - Re-esterified Triglyceride (rTG) Omega-3 ($1,200\ \text{mg EPA} + 800\ \text{mg DHA}$).
- **Calculations Verified**:
  - Python execution (`C:\vazus\.venv\Scripts\python.exe`):
    - $5,000\ \text{IU D3} = 125.0\ \mu\text{g}$.
    - $\text{Zn:Cu}$ elemental ratios: $15/1.5 = 10.0:1$, $30/2.0 = 15.0:1$, range $7.5:1$ to $20.0:1$.
- **Generated Deliverable**: `C:\vazus\.agents\reviewer_m4_1\review_report.md`.

---

## 2. Logic Chain
1. *Observation*: M3 protocol establishes an exceptionally high standard of chronobiological stacking (morning lipid solubilization for D3/K2 via CCK micellar formation; evening Mg for NMDA antagonism/GABA-A sleep induction) and co-factor kinetics (Mg-ATP CYP hydroxylation, GAMT methyl sparing via Creatine).
2. *Observation*: M3 correctly refined daily routine Selenium maintenance down to $50\text{--}100\ \mu\text{g/day}$ to prevent GPx1 hyper-scavenging of $\text{H}_2\text{O}_2$ insulin signaling messengers (SELECT trial safety).
3. *Observation*: M3 lacks critical pharmacological and clinical contraindications:
   - Vitamin K2 MK-7 ($100\text{--}200\ \mu\text{g}$) counteracts Warfarin/Coumadin anticoagulation, lowering INR.
   - $400\text{--}600\ \text{mg}$ elemental Magnesium risks hypermagnesemia in Stage 3b–5 CKD (eGFR $< 45\ \text{mL/min}$).
   - Daily $5\ \text{g}$ Creatine Monohydrate artificially elevates serum creatinine without GFR loss, creating a diagnostic trap unless **Cystatin C** is specified.
   - $4,000\text{--}5,000\ \text{IU}$ D3 risks severe hypercalcemia in granulomatous diseases (sarcoidosis, active TB).
4. *Inference*: While the core protocol structure is sound and APPROVED in principle, these clinical omissions represent material safety and diagnostic risks.
5. *Conclusion*: Verdict is **NEEDS_REVISION** pending incorporation of the four critical safety findings and recommendations into M3.

---

## 3. Caveats
- Review was conducted in a strict **review-only** role. No modification of `C:\vazus\.agents\orchestrator\M3_actionable_protocol.md` was performed directly.
- The review assumes normal adult baseline physiology; individualized clinical management requires baseline physician evaluation and blood laboratory panels as specified in Section 5 of M3.

---

## 4. Conclusion
The M3 Actionable Protocol is a landmark synthesis of male health optimization. The overall verdict is **NEEDS_REVISION** solely to incorporate mandatory clinical safety contraindications (Warfarin/VKAs, CKD hypermagnesemia threshold, granulomatous hypercalcemia) and the Creatine/Cystatin C diagnostic clarification.

---

## 5. Verification Method
To independently verify this peer review:
1. Inspect the written review report at `C:\vazus\.agents\reviewer_m4_1\review_report.md`.
2. Inspect the target protocol document at `C:\vazus\.agents\orchestrator\M3_actionable_protocol.md`.
3. Verify calculations by running:  
   `C:\vazus\.venv\Scripts\python.exe -c "print(5000 * 0.025); print(30/2.0); print(15/1.5)"`
4. Confirm presence of all 4 critical safety findings in `review_report.md`.
